Inactive Instrument

Highlights biOasis Technologies Inc Toronto S.E.

Equities

BTI

CA09064N1033

Highlights

Unlock all the news: Be the first to know and act before the market!

Bioasis Technologies Inc. Announces Terminating the Non-Exclusive Research Collaboration and Licensing Agreement with Chiesi Farmaceutici S.P.A	20/06/23	CI
Bioasis Technologies Explores and Evaluates Strategic Alternatives	24/01/23	CI
Midatech Pharma plc cancelled the acquisition of Bioasis Technologies Inc..	22/01/23	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	19/01/23	CI
Midatech Pharma plc entered into a definitive agreement to acquire Bioasis Technologies Inc. from The Lind Partners, LLC and others for $5.5 million.	12/12/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022	28/10/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022	29/07/22	CI
Bioasis Technologies Buys Phase 2 Ready Rare Orphan EGF Assets From Norwegian Company	16/06/22	MT
Bioasis Technologies Inc. Reports Earnings Results for the Full Year Ended February 28, 2022	15/06/22	CI
Bioasis Technologies and Neuramedy of South Korea Enter into Research Collaboration and License Agreement	11/05/22	MT
Bioasis Technologies Inc. and Neuramedy Co Ltd Enter into Research Collaboration and License Agreement	10/05/22	CI
Bioasis Technologies Inc. Enters Research Collaboration with Janssen Biotech, Inc	11/04/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2021	20/01/22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2021	28/10/21	CI
Bioasis Technologies Brief: nnounces Allowance of Japanese Patent Application in Japan Relating to Fusion Protein Comprising Iduronate-2-sulfatase	09/08/21	MT
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2021	29/07/21	CI
Bioasis Technologies Inc. Announces Positive Results from Efficacy Study of xB3™-IL-1RA in Model of Multiple Sclerosis	07/07/21	CI
Bioasis Technologies : Names New CFO	02/07/21	MT
Bioasis Technologies : and Oxyrane UK Agree to a Research Collaboration	30/06/21	MT
Bioasis Technologies Inc. and Oxyrane UK Ltd. Enter into a Research Collaboration	30/06/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights biOasis Technologies Inc Toronto S.E.

Equities

BTI

CA09064N1033

Highlights

Filters